Literature DB >> 22983588

Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.

Tim Pfeiffer1, Michael Schleuning, Jiri Mayer, Karl-Heinz Haude, Johanna Tischer, Stefanie Buchholz, Donald Bunjes, Gesine Bug, Ernst Holler, Ralf G Meyer, Hildegard Greinix, Christof Scheid, Maximilian Christopeit, Susanne Schnittger, Jan Braess, Günter Schlimok, Karsten Spiekermann, Arnold Ganser, Hans-Jochem Kolb, Christoph Schmid.   

Abstract

Based on molecular aberrations, in particular the NPM1 mutation (NPM1(mut)) and the FLT3 internal tandem duplication (Flt3-ITD), prognostic subgroups have been defined among patients with acute myeloid leukemia with normal karyotype. Whereas these subgroups are known to play an important role in outcome in first complete remission, and also in the indication for allogeneic stem cell transplantation, data are limited on their role after transplantation in advanced disease. To evaluate the role of molecular subgroups of acute myeloid leukemia with normal karyotype after allogeneic stem cell transplantation beyond first complete remission, we analyzed the data from 141 consecutive adults (median age: 51.0 years, range 18.4-69.3 years) who had received an allogeneic transplant either in primary induction failure or beyond first complete remission. A sequential regimen of cytoreductive chemotherapy (fludarabine, high-dose AraC, amsacrine) followed by reduced intensity conditioning (FLAMSA-RIC), was uniformly used for conditioning. After a median follow up of three years, overall survival from transplantation was 64 ± 4%, 53 ± 4% and 44 ± 5% at one, two and four years, respectively. Forty patients transplanted in primary induction failure achieved an encouraging 2-year survival of 69%. Among 101 patients transplanted beyond first complete remission, 2-year survival was 81% among patients with the NPM1(mut)/FLT3(wt) genotype in contrast to 43% in other genotypes. Higher numbers of transfused CD34(+) cells (hazard ratio 2.155, 95% confidence interval 0.263-0.964, P=0.039) and favorable genotype (hazard ratio 0.142, 95% confidence interval: 0.19-0.898, P=0.048) were associated with superior overall survival in multivariate analysis. In conclusion, patients with acute myeloid leukemia with normal karyotype can frequently be rescued after primary induction failure by allogeneic transplantation following FLAMSA-RIC. The prognostic role of NPM1(mut)/FLT3-ITD based subgroups was carried through after allogeneic stem cell transplantation beyond first complete remission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983588      PMCID: PMC3659981          DOI: 10.3324/haematol.2012.070235

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  41 in total

1.  Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

Authors:  Martin Bornhäuser; Thomas Illmer; Markus Schaich; Silke Soucek; Gerhard Ehninger; Christian Thiede
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

2.  Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.

Authors:  J Cloos; B F Goemans; C J Hess; J W van Oostveen; Q Waisfisz; S Corthals; D de Lange; N Boeckx; K Hählen; D Reinhardt; U Creutzig; G J Schuurhuis; Ch M Zwaan; G J L Kaspers
Journal:  Leukemia       Date:  2006-04-27       Impact factor: 11.528

3.  Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation.

Authors:  Norbert-Claude Gorin; Myriam Labopin; Jean-Michel Boiron; Niklas Theorin; Tim Littlewood; Shimon Slavin; Hildegard Greinix; Jean Yves Cahn; E Paolo Alessandrino; Alessandro Rambaldi; Arnon Nagler; Emmanuelle Polge; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2006-07-31       Impact factor: 44.544

Review 4.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

5.  NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia.

Authors:  Michela Palmisano; Tiziana Grafone; Emanuela Ottaviani; Nicoletta Testoni; Michele Baccarani; Giovanni Martinelli
Journal:  Haematologica       Date:  2007-09       Impact factor: 9.941

6.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Authors:  Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Cristina Mecucci; Claudia Tschulik; Massimo F Martelli; Torsten Haferlach; Wolfgang Hiddemann; Brunangelo Falini
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

7.  No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

Authors:  Rosemary E Gale; Robert Hills; Panagiotis D Kottaridis; Sivatharsini Srirangan; Keith Wheatley; Alan K Burnett; David C Linch
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

8.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Authors:  Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

9.  Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

Authors:  Patrice Chevallier; Jacques Delaunay; Pascal Turlure; Arnaud Pigneux; Mathilde Hunault; Richard Garand; Thierry Guillaume; Herve Avet-Loiseau; Nathalia Dmytruk; Stephane Girault; Noel Milpied; Norbert Ifrah; Mohamad Mohty; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

10.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.

Authors:  Christoph Schmid; Michael Schleuning; Rainer Schwerdtfeger; Bernd Hertenstein; Eva Mischak-Weissinger; Donald Bunjes; Stephanie V Harsdorf; Christoph Scheid; Udo Holtick; Hildegard Greinix; Felix Keil; Barbara Schneider; Michael Sandherr; Gesine Bug; Johanna Tischer; Georg Ledderose; Michael Hallek; Wolfgang Hiddemann; Hans-Jochem Kolb
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

View more
  11 in total

Review 1.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

2.  Allogeneic transplantation in primary refractory AML.

Authors:  P Ferguson; C Craddock
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

3.  An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Authors:  Paul Ferguson; Robert K Hills; Angela Grech; Sophie Betteridge; Lars Kjeldsen; Michael Dennis; Paresh Vyas; Anthony H Goldstone; Donald Milligan; Richard E Clark; Nigel H Russell; Charles Craddock
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

4.  Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Authors:  M Wattad; D Weber; K Döhner; J Krauter; V I Gaidzik; P Paschka; M Heuser; F Thol; T Kindler; M Lübbert; H R Salih; A Kündgen; H-A Horst; P Brossart; K Götze; D Nachbaur; C-H Köhne; M Ringhoffer; G Wulf; G Held; H Salwender; A Benner; A Ganser; H Döhner; R F Schlenk
Journal:  Leukemia       Date:  2017-01-19       Impact factor: 11.528

5.  Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.

Authors:  Christian Pfrepper; Anne Klink; Gerhard Behre; Thomas Schenk; Georg-Nikolaus Franke; Madlen Jentzsch; Sebastian Schwind; Haifa-Kathrin Al-Ali; Andreas Hochhaus; Dietger Niederwieser; Herbert Gottfried Sayer
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-30       Impact factor: 4.553

Review 6.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.

Authors:  P Tsirigotis; M Byrne; C Schmid; F Baron; F Ciceri; J Esteve; N C Gorin; S Giebel; M Mohty; B N Savani; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

7.  Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.

Authors:  Kateřina Kuželová; Barbora Brodská; Ota Fuchs; Marie Dobrovolná; Petr Soukup; Petr Cetkovský
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

8.  FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.

Authors:  Yeohan Song; John Magenau; Brian Parkin; Sung Won Choi; Yumeng Li; Thomas Braun; Lawrence Chang; Dale Bixby; David A Hanauer; Komal A Chughtai; Erin Gatza; Daniel Couriel; Steven Goldstein; Attaphol Pawarode; Pavan Reddy; Mary Riwes; James Connelly; Andrew Harris; Carrie Kitko; John Levine; Greg Yanik
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

9.  The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases.

Authors:  Shuro Yoshida; Hideho Henzan; Toshiyuki Ueno; Takuya Shimakawa; Yayoi Matsuo; Takuro Kuriyama; Noriyuki Saito; Ichiro Kawano; Akihiko Numata; Ken Takase; Tadafumi Iino; Tetsuya Eto
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-04-01

Review 10.  Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Ali Bazarbachi; Gesine Bug; Frederic Baron; Eolia Brissot; Fabio Ciceri; Iman Abou Dalle; Hartmut Döhner; Jordi Esteve; Yngvar Floisand; Sebastian Giebel; Maria Gilleece; Norbert-Claude Gorin; Elias Jabbour; Mahmoud Aljurf; Hagop Kantarjian; Mohamed Kharfan-Dabaja; Myriam Labopin; Francesco Lanza; Florent Malard; Zinaida Peric; Thomas Prebet; Farhad Ravandi; Annalisa Ruggeri; Jaime Sanz; Christoph Schmid; Roni Shouval; Alexandros Spyridonidis; Jurjen Versluis; Norbert Vey; Bipin N Savani; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2020-04-02       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.